Breaks Categories: News

WednesdayJan 20, 2021 10:46 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Lab Test Results of Patented Biopesticide Achieve 100% Control of Root-Rot Disease

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has announced successful test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores ("Aphanomyces"). The tests, conducted via an independent third-party facility, achieved 100% control of the root-rot disease Aphanomyces zoospores at economic application rates within 24 hours; Aphanomyces is a soil-borne disease that destroys key plant-based protein crops such as peas, lentils and legumes; current treatments are unable to control the disease. MustGrow next plans to test its proprietary biopesticide in larger-scale greenhouse and field settings. The company’s safe…

Continue Reading

WednesdayJan 20, 2021 10:22 am

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Hires IR Firm Torrey Hills Capital

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced its engagement of Rancho Santa Fe, California-based investor relations firm San Diego Torrey Hills Capital, Inc. ("Torrey Hills Capital") to deliver market awareness and investor relations services to IMEXF, subject to acceptance by the Canadian Securities Exchange ("CSE"). The move enables the company to cultivate an informed investor audience in both the U.S. and Canadian marketplaces. The company has engaged the firm at a rate of US$7,000 per month. Following the initial term…

Continue Reading

WednesdayJan 20, 2021 9:38 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Strategy for New Year; Outlines Expected Milestones

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released its business strategy and expected milestones for 2021. The company noted that in the coming year it anticipates commercialization of its proprietary rapid COVID-19 PCR (“PCR”) test as well as clinical validation of is exclusive transdermal and sublingual drug formulations; XPhyto is also planning on psychedelic API production, drug formulation and clinical integration in 2021. The announcement observed that XPhyto is on the cusp of transformational change as product development programs advance from the laboratory to the clinic. The company…

Continue Reading

WednesdayJan 20, 2021 9:14 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Executive Chairman Quoted in Elite Healthcare Article Noting How the Pandemic Might Impact Healthcare in 2021

Brain Scientific (OTCQB: BRSF) co-founder and executive chairman Boris Goldstein was quoted in a recent Elite Healthcare article titled “A Look at 2021 Healthcare with the Pandemic.” The article quoted a variety of clinicians and industry professionals who consider themselves futurists and who specialize in exploring predictions and possibilities based on present trends. The article discussed health care in 2021 from a variety of standpoints including individualized healthcare, technology timelines, conducting clinical trials, emerging emergency response, pediatric parameters, and facility design and work flows. Some trends were obvious, such as the dramatic growth of telehealth and various Internet of Medical Things;…

Continue Reading

TuesdayJan 19, 2021 11:14 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announced Definitive Agreements for $2.2 Million Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has entered into definitive agreements for the issuance and sale of more than 2 million shares of its common stock. The company announced that it has finalized definitive agreements with a number of institutional and accredited investors for the issuance and sale of approximately 2,200,000 common stock shares at $1.00 per share; the registered direct offering, priced at-the-market following Nasdaq rules, will result in gross proceeds of $2.2 million for the company. Predictive Oncology plans to use the net proceeds from…

Continue Reading

TuesdayJan 19, 2021 10:33 am

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Verifies Active Ingredient in Biopesticide Offering Positively Impacts Soil Health

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, this morning reported that third party studies have confirmed that Allyl Isothiocyanate ("AITC"), the active ingredient in MustGrow's mustard plant-based technology, has a positive impact on soil health, contributing to the environmental and ecological security of plant-based food supply and the planet. The company’s organic food-grade biopesticide utilizes the mustard seed's natural defense mechanism to control diseases, pests, and weeds. “The active ingredient, AITC, in MustGrow's mustard plant-based technology is perfect for use in modern, more sustainable pest control…

Continue Reading

FridayJan 15, 2021 9:48 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Featured in Pharma Mirror Magazine Article

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, was featured in a recent article published by Pharma Mirror Magazine. The article titled, “Neurology’s Growing Need for Disposable Technologies,” is written by Brain Scientific’s co-founder and executive chairman. The piece indicates that several studies have recently shown that the development of neurological conditions and symptoms are prevalent in COVID patients. “When conditions like seizures, stroke and metabolic encephalopathy emerge, suddenly in a COVID-19 patient, it can negatively impact treatment outcomes and morbidity rates,” the article reads. “Facing evidence that these symptoms are common in COVID patients at all…

Continue Reading

ThursdayJan 14, 2021 1:00 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Slated to Present at NobleCon17

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it will present at the upcoming NobleCon17, scheduled for Jan. 19–20, 2021. The virtual event is Noble Capital Markets’ annual investor conference. GNPX’s presentation will include a company overview and address the company’s recent progress on planned clinical trials focusing on the treatment of non-small cell lung cancer. Genprex president and CEO Rodney Varner will deliver the presentation to participating investors. The Genprex presentation is scheduled for Tuesday, Jan. 19, at 3:45 p.m. EST.  A replay of the presentation…

Continue Reading

ThursdayJan 14, 2021 11:58 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Subsidiary Sells Media to Top Research Medical Centers

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, POAI’s wholly owned subsidiary, sold media to top research medical centers in New York City and Boston. The announcement noted that those two sales are repeat orders and focus on culturing ovarian cancer cells with specific research goals; the company also announced an additional order that came from a private company conducting research on ovarian cancer. Experts forecast that the 3D cancer cell culture media market will grow at CAGR of approximately 11.3%, reaching $3.2 billion in sales…

Continue Reading

ThursdayJan 14, 2021 11:19 am

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Confirms Proceeds of C$1.5M from Warrant Exercise

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced its receipt of over C$1.5 million from the exercise of approximately 3.2 million common share purchase warrants at an average weighted exercise price of C$0.48 per share. The company intends to use the proceeds of the warrant exercise to advance its organic mustard plant-based crop protection technologies and for general working capital purposes. "Our shareholders have demonstrated strong support through continued exercise of warrants which further bolsters our cash position to over C$3.1 million," said MustGrow CEO…

Continue Reading